PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3310100

Second-trimester polyhydramnios: evaluation with US.

C J Sivit·M C Hill·J W Larsen·I M Lande
View original source ↗Export metadata ↓

Abstract

The sonograms of 40 patients with second-trimester polyhydramnios were reviewed to determine (a) whether fetal and maternal conditions occur as often during second-trimester polyhydramnios as during third-trimester polyhydramnios, (b) the frequency of persistence of polyhydramnios into the third trimester, and (c) how sonography can help in maternal and fetal management. Second-trimester polyhydramnios often (62%) persisted into the third trimester. The frequencies of maternal (25%) and fetal (12%) conditions were similar to those previously reported for third-trimester polyhydramnios. Fetal anomalies were always identified on the sonogram that initially demonstrated polyhydramnios. Fetal outcome was excellent in the nondiabetic patient with polyhydramnios in whom no fetal abnormalities were detected on sonograms. In polyhydramnios associated with maternal diabetes mellitus, however, the pregnancy was often (71%) complicated by premature labor or macrosomia. In such patients serial sonographic follow-up is indicated.

Explore related subjects

Amniotic FluidCongenital AbnormalitiesFemaleFetal DiseasesHumansPolyhydramniosPregnancyPregnancy Trimester, SecondRetrospective StudiesUltrasonographyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C J Sivit, M C Hill, J W Larsen, I M Lande. 1987. Second-trimester polyhydramnios: evaluation with US.. https://doi.org/10.1148/radiology.165.2.3310100

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

In-utero percutaneous cystoscopy in the management of fetal lower obstructive uropathy.

In fetuses with lower obstructive uropathy, sonography cannot establish the cause of obstruction. We assessed whether percutaneous fetal cystoscopy could be useful in the evaluation and treatment of obstructive defects in utero. We inserted a fibreoptic endoscope through the lumen of the needle or trocar into the fetal bladder at the time of vesicocentesis or vesicoamniotic-shunt placement and looked at the the urethra, bladder neck, and ureteral orifices. Urethral vesicoamniotic shunting was considered in suitable cases; otherwise a percutaneous shunt was inserted. Fetal cystoscopy was possible in 11 of 13 patients referred. The bladder mucosa appeared haemorrhagic or oedematous in three. The ureteral orifices were seen in 9/11 fetuses, dilation was seen in five, but was only suspected in two by ultrasound. Ureteral webs were noted in two other fetuses. Two of seven fetuses underwent urethral vesicoamniotic shunting; urethral patency was achieved with urethral probing alone in one fetus. The remaining four fetuses were shunted with a standard technique. Fetal cystoscopy helps define the underlying conditions responsible for sonographic findings of lower obstructive uropathy, and allows the introduction of new treatments.

Amniotic Fluid↗
PubMed1995

Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M.

Epidermal growth factor (EGF) is a 53-amino-acid mitogenic polypeptide present in a variety of tissues and fluids including kidney, urine, and amniotic fluid. An EGF isoform, des-Arg53-EGF, has been identified in urine and is the earliest metabolite generated in target cells upon EGF binding. In this study, purified carboxypeptidase M efficiently released the COOH-terminal arginine residue from EGF with a Km = 56 microM, kcat = 388 min-1, and kcat/Km = 6.9 microM-1 min-1. When EGF was incubated with urine or amniotic fluid, des-Arg53-EGF was the only metabolite detected. This conversion was blocked by immunoprecipitation with specific antiserum to carboxypeptidase M or by 10 microM DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (a carboxypeptidase M inhibitor), indicating that the major EGF metabolizing enzyme in these fluids is carboxypeptidase M. When incubated on a confluent monolayer of Madin-Darby canine kidney (MDCK) cells, EGF was readily converted to a single metabolite, des-Arg53-EGF, by carboxypeptidase M. To investigate one possible functional consequence of this conversion, mitogenic activities of EGF and des-Arg53-EGF were tested. Both peptides were equipotent in stimulating [3H]thymidine incorporation in MDCK cells at all doses tested. In addition, inhibition of the conversion of EGF to des-Arg53-EGF by the carboxypeptidase M inhibitor did not affect the mitogenic potency of EGF. These data indicate that carboxypeptidase M, present in a variety of cells and biological fluids, can convert EGF to des-Arg53-EGF. However, in contrast to many other peptide hormones whose activity depends on a final carboxypeptidase processing step, removal of Arg53 of EGF is not required for its mitogenic activity.

Amniotic Fluid↗